First Tracks Biotherapeutics, Inc. (TRAX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Daniel R. Faga
|
CEO, President & Director | 1.2M | -- | 1980 |
|
Dr. Paul F. Lizzul M.D.
|
Chief Medical Officer | 795.2k | -- | 1975 |
|
Mr. Ajim A. Tamboli C.F.A.
|
Chief Financial Officer | -- | -- | 1977 |
|
Nick Montemarano
|
Vice President of Investor Relations | -- | -- | -- |
|
Ms. Nicole Greene
|
Senior VP & General Counsel | -- | -- | -- |
|
Ms. Beth Mueller
|
Senior Vice President of Human Resources | -- | -- | -- |
|
Mr. Benjamin Stone
|
Chief Business Officer | -- | -- | 1991 |
|
Ms. Monique Da Silva
|
Senior Vice President of Corporate Affairs | -- | -- | -- |
|
Ms. Cailin Sibley FACR, M.D.
|
Senior Vice President of Translational Medicine | -- | -- | -- |
|
Mr. Carlos A. Garcia M.S.
|
Senior Vice President of CMC. | -- | -- | -- |
First Tracks Biotherapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 104
Description
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.
Corporate Governance
Upcoming Events
November 5, 2026 at 9:00 PM UTC
First Tracks Biotherapeutics, Inc. Earnings Date
Recent Events
May 8, 2026 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
